Ike Ogbaa

406 total citations
10 papers, 304 citations indexed

About

Ike Ogbaa is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Ike Ogbaa has authored 10 papers receiving a total of 304 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Endocrinology, Diabetes and Metabolism, 3 papers in Surgery and 3 papers in Molecular Biology. Recurrent topics in Ike Ogbaa's work include Diabetes Treatment and Management (8 papers), Metabolism, Diabetes, and Cancer (3 papers) and Pancreatic function and diabetes (3 papers). Ike Ogbaa is often cited by papers focused on Diabetes Treatment and Management (8 papers), Metabolism, Diabetes, and Cancer (3 papers) and Pancreatic function and diabetes (3 papers). Ike Ogbaa collaborates with scholars based in United States, United Kingdom and Germany. Ike Ogbaa's co-authors include Phillip Banks, Arthur Sands, Brian Zambrowicz, David R. Powell, Pablo Lapuerta, Kenny Frazier, Joel Freiman, Dennis Ruff, William T. Cefalu and Anne Turnage and has published in prestigious journals such as Diabetes Care, American Heart Journal and Nephrology Dialysis Transplantation.

In The Last Decade

Ike Ogbaa

10 papers receiving 296 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ike Ogbaa United States 8 255 162 118 36 32 10 304
Hristo Iliev Germany 5 214 0.8× 105 0.6× 119 1.0× 27 0.8× 31 1.0× 7 252
Harindra Rajasekeran Canada 5 278 1.1× 143 0.9× 101 0.9× 97 2.7× 40 1.3× 6 320
Lingli Zhou China 7 186 0.7× 78 0.5× 90 0.8× 14 0.4× 39 1.2× 17 251
Michito Ubukata Japan 8 295 1.2× 118 0.7× 166 1.4× 24 0.7× 52 1.6× 9 316
Seizo Okauchi Japan 11 282 1.1× 218 1.3× 169 1.4× 14 0.4× 25 0.8× 27 389
Aline M.E. Stades Netherlands 6 203 0.8× 85 0.5× 81 0.7× 17 0.5× 9 0.3× 11 249
Richard E. Pratley United States 7 240 0.9× 79 0.5× 79 0.7× 40 1.1× 55 1.7× 10 332
Jennifer Newman United States 4 326 1.3× 150 0.9× 125 1.1× 33 0.9× 38 1.2× 4 356
Weiling Leng China 9 197 0.8× 109 0.7× 125 1.1× 19 0.5× 17 0.5× 19 351
Jamie Diner United States 2 536 2.1× 293 1.8× 173 1.5× 14 0.4× 59 1.8× 3 588

Countries citing papers authored by Ike Ogbaa

Since Specialization
Citations

This map shows the geographic impact of Ike Ogbaa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ike Ogbaa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ike Ogbaa more than expected).

Fields of papers citing papers by Ike Ogbaa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ike Ogbaa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ike Ogbaa. The network helps show where Ike Ogbaa may publish in the future.

Co-authorship network of co-authors of Ike Ogbaa

This figure shows the co-authorship network connecting the top 25 collaborators of Ike Ogbaa. A scholar is included among the top collaborators of Ike Ogbaa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ike Ogbaa. Ike Ogbaa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Kohan, Donald E., Jonathan Barratt, Hiddo J.L. Heerspink, et al.. (2023). Targeting the Endothelin A Receptor in IgA Nephropathy. Kidney International Reports. 8(11). 2198–2210. 24 indexed citations
2.
Hompesch, Marcus, Oakpil Han, Michael Trautmann, et al.. (2021). Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study. BMJ Open Diabetes Research & Care. 9(1). e002208–e002208. 9 indexed citations
3.
Agarwal, Rajiv, Stefan D. Anker, Bertram Pitt, et al.. (2021). Importance of trial design when investigating cardiorenal outcomes in patients with CKD and T2D: Focus on CREDENCE and FIDELIO-DKD. American Heart Journal. 242. 162–162. 1 indexed citations
4.
Agarwal, Rajiv, Stefan D. Anker, Gerasimos Filippatos, et al.. (2021). Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrology Dialysis Transplantation. 37(7). 1261–1269. 36 indexed citations
5.
Zambrowicz, Brian, Pablo Lapuerta, Paul Strumph, et al.. (2014). LX4211 Therapy Reduces Postprandial Glucose Levels in Patients With Type 2 Diabetes Mellitus and Renal Impairment Despite Low Urinary Glucose Excretion. Clinical Therapeutics. 37(1). 71–82.e12. 34 indexed citations
6.
Rosenstock, Julio, William T. Cefalu, Pablo Lapuerta, et al.. (2014). Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Patients With Type 2 Diabetes on Metformin Monotherapy. Diabetes Care. 38(3). 431–438. 66 indexed citations
7.
Lapuerta, Pablo, Julio Rosenstock, Brian Zambrowicz, et al.. (2013). Study Design and Rationale of a Dose‐Ranging Trial of LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy. Clinical Cardiology. 36(7). 367–371. 12 indexed citations
8.
Zambrowicz, Brian, Zhi‐Ming Ding, Ike Ogbaa, et al.. (2013). Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes. Clinical Therapeutics. 35(3). 273–285.e7. 65 indexed citations
9.
10.
Aisenberg, Gabriel M., Luis A. Marcos, & Ike Ogbaa. (2009). Recurrent histoplasmosis in AIDS mimicking a colonic carcinoma. International Journal of STD & AIDS. 20(6). 429–430. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hristo Iliev Breakdown of academic impact, for papers by Harindra Rajasekeran Breakdown of academic impact, for papers by Lingli Zhou Breakdown of academic impact, for papers by Michito Ubukata Breakdown of academic impact, for papers by Seizo Okauchi Breakdown of academic impact, for papers by Aline M.E. Stades Breakdown of academic impact, for papers by Richard E. Pratley Breakdown of academic impact, for papers by Jennifer Newman Breakdown of academic impact, for papers by Weiling Leng Breakdown of academic impact, for papers by Jamie Diner
Rankless by CCL
2026